港股異動丨復星醫藥創逾一年新高 新冠病毒核酸檢測試劑盒獲FDA緊急使用授權
格隆匯4月22日丨復星醫藥(2196.HK)漲2.66%,報28.9港元,總市值740.7億港元。據美國食品藥品監督管理局(FDA)網站最新信息,復星醫藥的新型冠狀病毒2019-nCov核酸檢測試劑盒(熒光PCR法)於4月17日獲FDA簽發緊急使用授權(EUA)。這款核酸檢測試劑盒由復星醫藥控股子公司復星長征自主研發,此前已取得中國國家藥品監督管理局頒發的醫療器械註冊證,並獲得歐盟CE認證。美銀證券發表最新報告,大幅上調復星醫藥2022年每股盈利預測1.4倍,目標價自28港元上調至33港元,評級維持“買入”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.